Pbm

CVS Health Corporation

Articles

Mentioned

Top Role

Feb 10, 2026

First Mention

Apr 11, 2026

Last Mention

5.32

Relevance Score

Intelligence Brief

Based on 6 articles | Generated Apr 11, 2026

Overview

CVS Health Corporation operates as a leading pharmacy benefit manager (PBM) through its Caremark division, which plays a crucial role in controlling drug costs for insurers and employers. As the healthcare landscape shifts towards cost containment and value-based care, CVS's ability to negotiate rebates and manage formularies is more critical than ever.

Assets & Portfolio

CVS owns Caremark, a major PBM, and CVS Specialty, which focuses on high-cost specialty drugs. They also control a vast retail pharmacy network and have integrated Aetna, a major health insurer, providing a comprehensive healthcare service ecosystem.

Partnerships & Deals

CVS collaborates with pharmaceutical companies like Biogen to negotiate drug prices and rebates. They also work closely with insurers, including their own Aetna, to implement cost-saving strategies like step therapy, which aligns with broader industry trends towards value-based care.

Pipeline & Development

CVS is likely to expand its specialty pharmacy capabilities, focusing on high-cost areas like oncology and hepatitis C. They are also expected to enhance digital health services, potentially through partnerships or acquisitions, to better compete with emerging tech-driven players.

Competitive Position

CVS faces stiff competition from other PBMs like Express Scripts and emerging threats like Amazon Pharmacy, which is disrupting traditional pharmacy models. While CVS has a strong position due to its integrated healthcare services, the loss of generic fills to Amazon indicates vulnerability in their retail segment.

Technology & Innovation

CVS is increasingly integrating AI and data analytics into its operations, particularly in formulary management and patient engagement. However, they face challenges from more tech-savvy competitors like RxPBM.ai, which could outpace them if CVS doesn't accelerate its digital transformation.

Growth Outlook

CVS is on a steady growth trajectory, driven by its diversified healthcare offerings and strategic cost management initiatives. However, the pressure from new entrants and the need for digital innovation could impact their long-term growth if not addressed.

Industry Trend Fit

CVS is well-positioned to benefit from the industry's shift towards value-based care and cost containment strategies. Their integrated model with Aetna allows them to implement comprehensive cost-saving measures, but they must continue to innovate to stay ahead of tech-driven competitors.

Coverage Timeline

April 2026

Currax’s Nocdurna FDA Nod: $400M Branded Disruptor Upends Sleep Disorder Market Playbook The Week Mentioned

Apr 11, 2026

If Currax can secure tier-two positions at giants like UnitedHealthcare or CVS Caremark, there’s a path back to $100 million-plus annually.

Specialty Spend Surge: How 2026 Hepatitis C Therapy Innovations Are Redistributing $10B in Commercial Pharmacy Payments Data Mentioned

Apr 11, 2026

PBM-owned specialty pharmacies, think Express Scripts or CVS Specialty, have leaned on formulary power to squeeze out every possible rebate dollar.

CVS Health’s Tighter Grip: Biologics Prior Authorization Denials Surge to 42% in 2026 Data Primary Subject

Apr 11, 2026

A 42% denial rate for biologics prior authorizations through CVS Caremark in the first half of 2026 says plenty about what’s happening in the pharmacy benefit manager world right now.

FTC's Latest Actions Against PBMs: The Future of Pharmaceutical Distribution and Market Power Dynamics Policy Primary Subject

Apr 11, 2026

CVS Health, today’s largest PBM owner, also runs the country’s biggest retail pharmacy and controls Aetna, a giant among health plans.

Amazon Pharmacy’s Disruption: 2025 PBM Contracting Challenges and Prescription Fulfillment Shifts Negotiations Competitor

Apr 11, 2026

Walgreens and CVS together lost about 250,000 monthly generic fills to Amazon between January and May alone.

How Pfizer's Oncology Pipeline Drives 2025 Specialty Pharmacy Network Negotiations with PBMs Negotiations Mentioned

Apr 11, 2026

Cigna’s Evernorth and CVS Health’s Caremark have slashed their oncology specialty networks to six to eight pharmacies, a sharp cut from 15 in 2019.

Spinraza’s 2025 Cliff: Biogen, Patent Expiry, and the New Pricing Squeeze Money Deal Party

Apr 4, 2026

Major PBMs, CVS, Cigna, the usual suspects, have already managed to wrest bigger rebates from Biogen late in Spinraza’s lifecycle.

Why Aetna’s 2026 Formulary Drop Hits Eliquis:and What It Means for Anticoagulants Data Mentioned

Apr 2, 2026

Aetna’s move exposes a broader industry shift: both Express Scripts and CVS Caremark are tightening their anticoagulant rosters for the same period.

March 2026

Aetna’s 2026 Step Therapy Expansion: Biologic Manufacturers Face $7B Battleground Negotiations Mentioned

Mar 26, 2026

For context, Aetna’s parent CVS Health reported under $3 billion in drug cost savings from all pharmacy benefit optimizations in 2025.

State PBM Legislation 2025-2026: National Chains Absorb, Independents Scramble Policy Primary Subject

Mar 21, 2026

Put that next to CVS Health, which books over $2.5 billion in legal and compliance costs annually.

February 2026

The Revolving Door Between PBMs and Regulators: Career Paths That Shape Drug Pricing Policy People Mentioned

Feb 10, 2026

At this point, it’s almost routine.